Evidence map›Paper›PMID 33388878›Full record

ReviewWorld journal of urology2021

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials.

Alex Z Wang, Amir H Lebastchi, Luke P O'Connor, Michael Ahdoot, Sherif Mehralivand, Nitin Yerram, Samir S Taneja, Arvin K George, Rafael Sanchez-Salas, John F Ward and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Irreversible Electroporation for Prostate Cancer.Life (Basel, Switzerland) · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alex Z WangUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Amir H LebastchiUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. amir.lebastchi@nih.gov.
Luke P O'ConnorUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael AhdootUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sherif MehralivandMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nitin YerramUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Samir S TanejaDivision of Urologic Oncology, Department of Urology, NYU Langone Health, NYU School of Medicine, New York, NY, USA.
Arvin K GeorgeDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA.
Rafael Sanchez-SalasDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
John F WardDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pilar LagunaDepartment of Urology, Istanbul Medipol University, Istanbul, Turkey.
Jean de la RosetteDepartment of Urology, Istanbul Medipol University, Istanbul, Turkey.
Peter A PintoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
6 · The paper itself

Abstract

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.

Indexed as

Ablation TechniquesClinical Trials as TopicHumansMaleOrgan Sparing TreatmentsPractice Guidelines as TopicProstatic NeoplasmsRisk AssessmentFocal therapyMRIprostate cancer

Identifiers

PMID33388878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.